Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) shares traded -1.96% lower at $10.00 on Wall Street last session.
ZNTL stock price is now -50.68% away from the 50-day moving average and -55.60% away from the 200-day moving average. The market capitalization of the company currently stands at $706.10M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target reduced from $38 to $12, Wedbush Downgraded its rating from Outperform to Neutral for Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL).
In other news, Brownstein Carrie, Chief Medical Officer sold 10,628 shares of the company’s stock on Oct 04. The stock was sold for $207,298 at an average price of $19.50. Upon completion of the transaction, the Chief Medical Officer now directly owns 105,685 shares in the company, valued at $1.06 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 04, Chief Scientific Officer Bunker Kevin D. sold 6,068 shares of the business’s stock. A total of $118,355 was realized by selling the stock at an average price of $19.50. This leaves the insider owning 859,089 shares of the company worth $8.59 million. Insiders disposed of 215,259 shares of company stock worth roughly $2.15 million over the past 1 year. A total of 9.29% of the company’s stock is owned by insiders.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) opened at $10.03 on Wednesday. During the past 12 months, Zentalis Pharmaceuticals Inc has had a low of $9.74 and a high of $31.46. As of last week, the company has a debt-to-equity ratio of 0.09, a current ratio of 8.97, and a quick ratio of 8.97. The fifty day moving average price for ZNTL is $20.27 and a two-hundred day moving average price translates $22.52 for the stock.
The latest earnings results from Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$1.85, missing analysts’ expectations of -$1.04 by -0.81. This compares to -$0.96 EPS in the same period last year. The company reported revenue of $62.72 million for the quarter, compared to $54.19 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 15.73 percent.
Zentalis Pharmaceuticals Inc(ZNTL) Company Profile
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company’s products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics: and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
